-
Product Insights
Split-Dalmatia_Enlight Renewable Wind Farm
Split-Dalmatia_Enlight Renewable Wind Farm is an onshore wind project located in Split-Dalmatia, Croatia. The project is owned and being developed by Enlight Renewable Energy Ltd. The project is expected to come online in 2025. Empower your strategies with our Split-Dalmatia_Enlight Renewable Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....
-
Product Insights
Split Rail Solar PV Park
Split Rail Solar PV Park is a solar PV project located in Missouri, United States. The project is owned and being developed by Invenergy LLC. The project is at the permitting stage. Empower your strategies with our Split Rail Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [Strains A + B] (Tetravalent, Split Virion) Vaccine in Influenzavirus A Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Influenza [Strains A + B] (Tetravalent, Split Virion) Vaccine in Influenzavirus A Infections Drug Details:Vaccine is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [Strains A + B] (Tetravalent, Split Virion) Vaccine in Influenzavirus B Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Influenza [Strains A + B] (Tetravalent, Split Virion) Vaccine in Influenzavirus B Infections Drug Details:Vaccine is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [Strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (Quadrivalent, Split Virion) Vaccine in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Influenza [Strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (Quadrivalent, Split Virion) Vaccine in Seasonal Influenza report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Thematic Analysis
NewSocial Media in Banking – Thematic Intelligence
Social Media in Banking Thematic Report Overview Social media companies will increasingly diversify away from their ad-funded business model in the face of increased regulatory scrutiny. Social media in banking thematic report maps out the prospects of social media giants for a deep assault on financial services, and how incumbent banks might respond. The report shares findings from GlobalData’s 2023 Financial Services Consumer Survey, which covers consumer openness to a wide variety of different types of financial services from different...
-
Macroeconomic Analysis
NewNorway PESTLE Insights – A Macroeconomic Outlook Report
Mining, manufacturing, and utilities contributed 41.7% to the gross value added (GVA) in 2023, followed by financial intermediation, real estate, and business activities (12.4%) and wholesale, retail, and hotels (6.1%). In nominal terms, the three sectors are forecast to grow by 4.5%, 5.3%, and 5.2%, respectively, in 2024. Three major cities in Norway generated 39.9% of the country’s GDP in 2023 and comprised 33.5% of the country’s population, as of 2023.
-
Macroeconomic Analysis
NewAustralia PESTLE Insights – A Macroeconomic Outlook Report
Mining, manufacturing and utilities activities contributed 22.6% to the gross value added (GVA) in 2023, followed by financial intermediation, real estate and business activities (21.5%), wholesale, retail and hotels activities (9.8%). In nominal terms, the three sectors are expected to grow by 3.7% each in 2024. Four major metropolitan regions in Australia comprised 57.3% of the country’s population and accounted for 59.5% of the country’s GDP in 2023, according to GlobalData’s cities database.
-
Macroeconomic Analysis
NewRussia PESTLE Insights – A Macroeconomic Outlook Report
Metropolitan areas of Moscow and Saint Petersburg account for nearly 19.7% of Russia’s population and 40.1% of its GDP in 2023, according to GlobalData’s cities database. In November 2023, the government announced to invest RUB1.3 trillion ($15.4 billion) to foster development in Russia railways infrastructure in 2024.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roneparstat in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roneparstat in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roneparstat in Refractory Multiple Myeloma Drug Details: Roneparstat (SST-0001) is under...